STOCK TITAN
  1. Home
  2. News
  3. LPCN

Lipocine Inc - LPCN STOCK NEWS

Welcome to our dedicated news page for Lipocine (Ticker: LPCN), a resource for investors and traders seeking the latest updates and insights on Lipocine.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lipocine's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lipocine's position in the market.

News
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
Rhea-AI Summary
Lipocine Inc. (NASDAQ: LPCN) announces positive results from a Phase 2 clinical trial for LPCN 2401, showing significant improvements in body composition. The treatment led to increased lean mass by 4.4% and decreased fat mass by 6.7%. Additionally, android fat decreased by 4.1% and bone mineral content increased by 2.8%. The treatment was well-tolerated, with adverse events similar to placebo. Results suggest the potential for LPCN 2401 to be used in combination with incretin mimetics or as a monotherapy post discontinuation, offering promising outcomes for weight management interventions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
clinical trial
-
News
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
Rhea-AI Summary
Lipocine Inc. (NASDAQ: LPCN) reports positive Phase 2 results for LPCN 1148 in cirrhosis management. The study showed increased Skeletal Muscle Index (SMI) maintained through 52 weeks, fewer Hepatic Encephalopathy (HE) events, and well-tolerated therapy. LPCN 1148 aims to address sarcopenia and OHE recurrence, potentially becoming a standard of care for cirrhosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
clinical trial
-
News
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
Rhea-AI Summary
Lipocine Inc. announces completion of study enrollment and dosing of the first cohort in a pivotal pharmacokinetic study for LPCN 1154, an oral brexanolone to treat postpartum depression. The company expects topline results from the study in late Q2 2024. PPD affects around 500,000 women annually in the US, with an estimated 175,000 suffering from moderate to severe PPD. LPCN 1154 aims to provide a fast-acting, short-duration treatment option for PPD patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.91%
Tags
none
News
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
Rhea-AI Summary
Lipocine Inc. announced positive results from PK bridge studies of LPCN 1154 for postpartum depression and LPCN 1148 for decompensated cirrhosis. The company also entered into an exclusive License Agreement for TLANDO with Verity Pharma. Financially, Lipocine reported a net loss of $16.4 million for the year ended December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
earnings
-
News
Lipocine to Present at 36th Annual Roth Conference
Rhea-AI Summary
Lipocine Inc. (LPCN) announced that Dr. Mahesh V. Patel, President and CEO, will participate in a fireside chat at the 36th Annual Roth Conference on March 18, 2024. The event will take place in Laguna Niguel, CA, with details provided for investors to attend or arrange meetings. The company's focus on CNS disorders is highlighted, emphasizing its commitment to engaging with investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
conferences
-
News
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
Rhea-AI Summary
Lipocine Inc. announces positive results from a multi-dose clinical study confirming the 48-hour dosing regimen for LPCN 1154, an oral neurosteroid for the treatment of postpartum depression. The company is on track for Q2-24 pivotal study topline results and planned Q4-24 NDA filing. The results support the design of the planned NDA enabling pivotal study, positioning LPCN 1154 as a highly effective, oral, fast-acting, and short-duration treatment option for PPD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.07%
Tags
none
News
Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals
Rhea-AI Summary
Lipocine Inc. announced the transition of TLANDO® commercialization to Verity Pharma, ensuring patient access to the first oral testosterone replacement therapy approved by the FDA. The exclusive license agreement with Gordon Silver Limited will see Lipocine receive a total of $11 million, with $5 million already received and future payments of $2.5 million and $1 million by January 2025 and 2026, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
none
-
News
Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada
Rhea-AI Summary
Lipocine Inc. (NASDAQ: LPCN) has entered into an exclusive licensing agreement with Verity Pharmaceuticals, Inc. (Verity Pharma) for the commercialization of TLANDO, the first and only oral testosterone replacement therapy (TRT) option approved by the US FDA that does not require dose titration. The agreement includes an $11 million license fee, up to $259 million in development and sales-based commercial milestone payments, and tiered royalties on net sales of TLANDO franchise products. Verity Pharma will be responsible for regulatory and marketing obligations in the U.S. and Canada, while Lipocine retains all rights to the TLANDO franchise for territories outside the U.S. and Canada, and all rights to non-TRT indications globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.16%
Tags
none
-
News
Lipocine to Present at Biotech Showcase 2024
Rhea-AI Summary
Lipocine Inc. (NASDAQ: LPCN) to present at the Biotech Showcase and host institutional investor and partnering meetings at the event and at a Corporate Access Event organized by LifeSci Partners on January 8 - 10, 2024, in San Francisco, California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.41%
Tags
conferences
News
Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023
Rhea-AI Summary
Lipocine Inc. (NASDAQ: LPCN) announces positive results of its Phase 2 study evaluating LPCN 1148 for sarcopenia and other clinically meaningful outcomes at The Liver Meeting 2023. The study demonstrates improvements in sarcopenia and hepatic encephalopathy, with an ongoing open label extension showing continued improvement in patients converting from placebo to LPCN 1148. Dr. Arun Sanyal, MD, presents the results at the conference, with an Open Label Extension ongoing and further data expected in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.2%
Tags
clinical trial
Stock LPCN logo
Lipocine Inc

Nasdaq:LPCN

LPCN Rankings

#5031 Ranked by Market Cap
#5045 Ranked by Stock Gains
N/A Ranked by Dividends

LPCN Stock Data

30.88M
5.16M
3.03%
9.17%
2.05%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Salt Lake City

About LPCN

lipocine inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products. the company develops drugs based on hydroance, a drug delivery technology. it primarily focuses on developing oral versions of several hormones for use in men and women health. the company’s lipid-based technology platform offers non-invasive delivery solutions for small polar organics and macromolecules. it also offers custom drugs for pharmaceutical/biotechnology companies. lipocine inc. was founded in 1997 and is headquartered in salt lake city, utah.